BI investigates cancer ‘dark antigens’ with UK’s EnaraBoehringer Ingelheim has signed a strategic collaboration with UK biotech Enara Bio, focused on finding ways to fight Share XBI investigates cancer ‘dark antigens’ with UK’s Enarahttps://pharmaphorum.com/news/boehringer-to-investigate-dark-antigens-with-uk-cancer-specialist-enara/
Boehringer, Lilly’s Jardiance ties to match AZ’s Farxiga with heart failure labelBoehringer and Eli Lilly have moved closer to a heart failure indication for their SGLT2 inhibitor Jardiance, as Share XBoehringer, Lilly’s Jardiance ties to match AZ’s Farxiga with heart failure labelhttps://pharmaphorum.com/news/boehringer-lillys-jardiance-ties-to-match-azs-farxiga-with-heart-failure-label/
Boehringer buys NBE for €1.18bn, adding cancer ADC expertiseBoehringer Ingelheim has expanded its oncology focus for the second time this week by buying Swiss biotech NBE-Therapeutics, Share XBoehringer buys NBE for €1.18bn, adding cancer ADC expertisehttps://pharmaphorum.com/news/boehringer-buys-nbe-for-e1-18bn-adding-cancer-adc-expertise/
Boehringer axes IPF deal with South Korea’s Bridge Biotherapeutics over toxicity concernsBoehringer Ingelheim and South Korea’s Bridge Biotherapeutics have decided to axe their collaboration over a potential new drug Share XBoehringer axes IPF deal with South Korea’s Bridge Biotherapeutics over toxicity concernshttps://pharmaphorum.com/news/boehringer-axes-ipf-deal-with-south-koreas-bridge-therapeutics-over-toxicity-concerns/
Boehringer, Yale trial digital tech in heart failurePatients with heart failure often have a dismal prognosis as the condition usually worsens over time, but a Share XBoehringer, Yale trial digital tech in heart failurehttps://pharmaphorum.com/news/boehringer-yale-trial-digital-tech-in-heart-failure/
BI signs schizophrenia app deal with Click TherapeuticsBoehringer Ingelheim has signed a $500 million contract with Click Therapeutics to co-develop and market a digital treatment Share XBI signs schizophrenia app deal with Click Therapeuticshttps://pharmaphorum.com/news/bi-signs-schizophrenia-app-deal-with-click-therapeutics/
AZ trumpets Farxiga survival data in renal disease at ESC 2020AstraZeneca’s Farxiga is already ahead of rivals in the SGLT2 inhibitor field in heart failure, and now looks Share XAZ trumpets Farxiga survival data in renal disease at ESC 2020https://pharmaphorum.com/news/az-trumpets-farxiga-survival-data-in-renal-disease-at-esc-2020/
NHS looks for digital pioneers to reshape services during pandemicA fellowship programme is looking for digital pioneers to design and lead service transformation projects in England’s NHS Share XNHS looks for digital pioneers to reshape services during pandemichttps://pharmaphorum.com/news/nhs-looks-for-digital-pioneers-to-reshape-services-during-pandemic/
Redx shares soar after IPF drug licence deal with AstraZenecaShares in Redx Pharma were soaring this morning after it licensed its preclinical fibrotic disease drug RXC006 to Share XRedx shares soar after IPF drug licence deal with AstraZenecahttps://pharmaphorum.com/news/redx-shares-soar-after-ipf-drug-deal-with-astrazeneca/
